Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.
Multilamellar vesicles containing nystatin (NYS) were compared with vesicles containing the free drug for toxicity to erythrocytes and for antifungal activity in vitro. Liposomal nystatin was as active as free NYS was against a wide variety of yeasts and fungi. The antifungal activity against Candida albicans was maintained with different liposome compositions and without sterols. Liposome encapsulation also protected the erythrocytes from the toxicity of free NYS.
Mehta
R T
RT
Department of Clinical Immunology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston.
Hopfer
R L
RL
Gunner
L A
LA
Juliano
R L
RL
Lopez-Berestein
G
G
D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy*; D002214:Capsules; D002851:Chromatography, High Pressure Liquid; D004912:Erythrocytes / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008081:Liposomes; D008826:Microbial Sensitivity Tests; D009761:Nystatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D002214:Capsules; D008081:Liposomes; D009761:Nystatin